Eupraxia Pharmaceuticals Inc. Common Stock (EPRX) Stock Price

EPRXStock
$6.62+14.58%52W
Market Cap$437.41M
P/E—
PEG Ratio—
Div yield—
Beta1.12

EPRX Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-15.27%
Price vs S&P 500 (4W)-20.56%
VGM Score65.53

EPRX Earnings Surprise History

QuarterReport dateEPS estimateEPS actualSurprise
Q2 2026-$0.23-$0.23+0.00%(+$0.00)
Q4 2025-$0.16-$0.37-133.34%(-$0.21)
Q3 2025-$0.19-$0.19+1.04%(+$0.00)
Q2 2025-$0.18-$0.26-40.54%(-$0.08)

EPRX Analyst Recommendations

Jun 2026
Jul 2026
Aug 2026
Sep 2026
4.27
4.27
4.27
4.27

Industry Peers — Pharmaceuticals(574)

SymbolValue ScoreGrowth ScoreMomentum ScoreP/S Ratio (TTM)Revenue Growth TTM (YoY)Gross Margin (TTM)EPS Growth (5Y)Price
EPRXEupraxia Pharmaceuticals Inc. Common Stock
——B————$6.62
LLYEli Lilly & Co.DBA14.9x49.6%83.4%27.6%$1257.03
JNJJohnson & JohnsonDCB6.2x7.8%67.7%14.9%$255.56
ABBVABBVIE INC.DCA7.8x10.4%72.8%-2.9%$285.42
MRKMerck & Co., Inc.DCA5.4x4.6%77.3%21.2%$145.95
NVSNovartis AGCCB4.9x3.3%75.0%15.3%$150.62
AZNAstraZeneca PLCCBB4.3x8.6%81.3%21.9%$165.41
ABTAbbott LaboratoriesCCB3.9x8.1%56.8%8.2%$104.89
NVONovo-Nordisk A/SBCC3.5x5.6%80.7%20.7%$38.83
PFEPfizer Inc.CDA2.6x-0.2%74.7%-3.5%$29.58
VRTXVertex Pharmaceuticals IncDCB10.1x10.2%86.0%8.3%$499.74

About Eupraxia Pharmaceuticals Inc. Common Stock

Eupraxia Pharmaceuticals is a clinical-stage biotech company developing extended-release, locally delivered therapeutics using its proprietary Diffusphere technology. Its lead candidate, EP-104, targets osteoarthritis and eosinophilic esophagitis, addressing unmet medical needs through improved drug delivery profiles.